Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets

Nephrology Dialysis Transplantation

Volumn 16, Issue 5, 2001, Pages 987-993

  Sagedal, Solbjørg ^a   Hartmann, Anders ^a   Sundstrøm, Kristina ^a   Bjørnsen, Stine ^a   Brosstad, Frank ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Dalteparin; Haemodialysis; Plasmin antiplasmin; Prothrombin fragment 1 + 2 (PF1 + 2); Thrombin antithrombin; Thromboglobulin

Indexed keywords

ANTICOAGULANT AGENT; ANTIPLASMIN; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; LUPUS ANTICOAGULANT; PLASMIN; PROTHROMBIN COMPLEX; THROMBIN ANTITHROMBIN COMPLEX; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ACTIVITY; EQUIPMENT; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HEMODIALYSIS; HUMAN; LUNG EMBOLISM; MALE; PARAMETER; PREVENTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOPHILIA; VEIN CATHETERIZATION;

EID: 0035025371     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.5.987     Document Type: Article

References (26)

1. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Fauchald P, Brosstad F. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999; 14: 1943-1947
2. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-278
3. Amhühl PM, Wüthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 1997; 112: 2355-2364
4. Matzdorff AC, Kemkes-Matthes B, Voss R, Pralle H. Comparison of b-Thromboglobulin, Flow Cytometry, and Platelet Activation. Haemostasis 1996; 26: 98-106
5. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536
6. Ljungberg B, Jacobson SH, Lins IE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992; 38: 97-100
7. Suzuki T, Kazuo O, Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan. Semin Thromb Hemost 1990; 16: 46-54
8. Warkentin T, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335
9. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500
10. Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438-442
11. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674
12. Kurihara Y, Nakayama H, Nakagawa S. Plasma β-thromboglobulin and platelet factor 4 in renal insufficiency. Thrombosis Res 1980; 18: 557-560
13. H van Hulsteijn, Ad van Es, Bertina R, Briet E. Plasma beta-thromboglobulin and platelet factor 4 in renal failure. Thrombosis Res 1981; 24: 175-180
14. Adler AJ, Lundin AP, Friedman EA, Berlyne GM. Effect of hemodialysis on plasma beta thromboglobulin levels. Trans Am Soc Artif Intern Organs 1979; 25: 347-350
15. Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human b-thromboglobulin and platelet factor 4. Thrombosis Res 1978; 12: 851-861
16. Zahavi J, Kakkar VV. β-Thromboglobulin - a specific marker of in-vivo platelet release reaction. Thrombosis Haemostas 1980; 44: 23-29
17. Guzzo J, Niewiarowski S, Musial J et al. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure. J Lab Clin Med 1980; 96: 102-113
18. Knudsen F, Dyerberg J. Platelets and antithrombin III in uraemia: the acute effect of haemodialysis. Scand J Clin Lab Invest 1985; 45: 341-347
19. Green D, Santhanam S, Krumlovsky FA, del Greco F. Elevated β-thromboglobulin in patients with chronic renal failure: effect of hemodialysis. J Lab Clin Med 1980; 95: 679-685
20. Cella G, Vertolli U, Naso A et al. Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb Res 1996; 81: 671-677
21. Kario K, Matsou T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronc dialysis patients. Thromb Res 1992; 67: 105-113
22. Lip GYH, Lip PL, Zarifis J et al. Fibrin D-Dimer and b-Thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-431
23. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int 1997; [Suppl. 62]: S53-55
24. De Lima JJG, Sesso R, Abensur H et al. Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions. Nephrol Dial Transplant 1995; 10: 1708-1713
25. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420
26. Rugman FP, Jenkins JA, Duguid JK, Bolton Maggs P, Hay CRM. Prothrombin fragment F1+2: correlations with cardiovascular risk factors. Blood Coag Fibrin 1994; 5: 335-340